Direct access

Share price calculator

News & Events

Investor Presentation


Presentation by Jean-Paul Agon, Chairman and CEO, at the Barclays Global Consumer Staples Conference

All news

Financial calendar

30  July 2019

2019 Half-Year Sales and Results

All dates


Investor relations and Financial analysts
+33 (0)1 47 56 86 82
Individual shareholder relations
+33 (0)1 47 56 83 02
From France
0 800 66 66 66
From outside France +33 (0)1 40 14 80 50
Your contacts

Frequently Asked Questions

Answers to the most frequently asked questions can be found online.

Questions and Answers

Focus on the Annual General Meeting 2017

Article published on 24.05.2017

Each year the Annual General Meeting is an important occasion for L’Oréal shareholders. On 20 April 2017, some 1,900 shareholders participated in this event which took place at the Palais des Congrès in Paris.

Main facts

The Annual General Meeting is an opportunity to learn more about the results and prospects of the group by dealing with several topics during a question and answer session. Amongst other items, Paul Bulcke, Chairman of the Board of Directors, Nestlé S.A., was nominated as a member of the L’Oréal Board of Directors.

The Annual General Meeting was also a great opportunity to look back on the group’s performance, as mentioned by Jean-Paul Agon, Chairman and CEO, in his address:

“2016 was another good year for L’Oréal. We accelerated our growth, and once again outperformed the beauty market, with solid growth at +4%, thus strengthening our position as number 1.”

During the question and answer session, shareholders raised many topics. For example, one issue raised was the absence of endocrine disrupters in L’Oréal products. Hervé Toutain, former Global Head Worldwide Product Safety, Regulatory Affairs & Claims Substantiation, who is now -Senior Vice President - Product Stewardship & Public Affairs gave the following reponse:

“In the group we do not use endocrine disruptors, as defined by the World Health Organisation, as none of our substances interferes with the hormonal system, causing damaging effects for human health. We take the question of endocrine modulation very seriously, and it has been an integral part of our safety assessment approach for more than 15 years.”

Paul Bulcke, a new member of the L’Oréal Board of Directors.

Since 1979, Mr Paul Bulcke had an international career, in particular in Latin America and Europe. In 2004, he was appointed Director for Zone Americas. Between 2008 and 2016, he was the Chief Executive Officer of Nestlé S.A. On 6 April 2017, he was appointed Chairman of the Board of Directors, Nestlé S.A.

A special edition of the Letter to Shareholders concerning the Annual General Meeting can be found online at

Share price

L'Oréal share
CAC 40

Find out more